BullFrog AI Holdings (BFRGW) Other financing activities (2023 - 2024)
BullFrog AI Holdings' (BFRGW) quarterly Other financing activities came in at $105816.0 in Q1 2024, up 107.08% quarter-over-quarter from -$1.5 million in Q3 2023.
Powered by 
Analysis
BullFrog AI Holdings (BFRGW) Other financing activities (2023 - 2024) Analysis & Trends
BullFrog AI Holdings (BFRGW) has reported Other financing activities for 2 consecutive years, with $105816.0 the latest figure, recorded in Q1 2024.
- For the quarter ending Q1 2024, Other financing activities changed N/A year-over-year to $105816.0; the trailing twelve-month figure through Dec 2024 stood at $105816.0 (changed N/A YoY), and the FY2024 full-year result was $105816.0, down 92.92% from the prior year.
- Other financing activities improved to $105816.0 in Q1 2024 per BFRGW's latest filing, from -$1.5 million in the prior quarter.
- Across five years, Other financing activities topped out at $1.5 million in Q2 2023 and bottomed at -$1.5 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.04 Bn | 197.05 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.32 Bn | 178.14 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.20 Bn | 124.35 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.41 Bn | 74.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.58 Bn | 56.39 Bn | 1.37 Bn |
| 6 | Moderna | 54.71 Bn | 49.57 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.15 Bn | 30.84 Bn | 992.69 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn |
| 10 | BullFrog AI Holdings | 1.84 Mn | -5.08 Mn | 106,899.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 105,816.00 |
| Sep 30, 2023 | -1.49 Mn |
| Jun 30, 2023 | 1.49 Mn |